The American Society of Clinical Oncology meets every spring. It's attended by some 30,000 people and hosts 4,000 presentations.
Investors like us love ASCO because of the so-called "ASCO Effect" - a hefty surge in cancer-focused biotech stocks that always accompanies the start of this meeting.
And we usually recommend an oncology stock or two ourselves.
This year's ASCO turned us on to an important new trend - one that's shaping up as the next big profit opportunity in biotech. Full Story